Daniel A. Norris

5.6k total citations · 4 hit papers
38 papers, 3.7k citations indexed

About

Daniel A. Norris is a scholar working on Molecular Biology, Genetics and Surgery. According to data from OpenAlex, Daniel A. Norris has authored 38 papers receiving a total of 3.7k indexed citations (citations by other indexed papers that have themselves been cited), including 21 papers in Molecular Biology, 15 papers in Genetics and 5 papers in Surgery. Recurrent topics in Daniel A. Norris's work include Neurogenetic and Muscular Disorders Research (15 papers), RNA Interference and Gene Delivery (6 papers) and RNA modifications and cancer (6 papers). Daniel A. Norris is often cited by papers focused on Neurogenetic and Muscular Disorders Research (15 papers), RNA Interference and Gene Delivery (6 papers) and RNA modifications and cancer (6 papers). Daniel A. Norris collaborates with scholars based in United States, Canada and United Kingdom. Daniel A. Norris's co-authors include C. Frank Bennett, Richard S. Geary, Rosie Z. Yu, Kathie M. Bishop, Patrick J. Sinko, Claudia A. Chiriboga, Darryl C. De Vivo, Jacqueline Montes, Frank Rigo and Gene Hung and has published in prestigious journals such as The Lancet, Nucleic Acids Research and Journal of Clinical Oncology.

In The Last Decade

Daniel A. Norris

38 papers receiving 3.6k citations

Hit Papers

align trajectories

What are hit papers?

Hit papers significantly outperform the citation benchmark for their cohort. A paper qualifies if it has ≥500 total citations, achieves ≥1.5× the top-1% citation threshold for papers in the same subfield and year (this is the minimum needed to enter the top 1%, not the average within it), or reaches the top citation threshold in at least one of its specific research topics.

Treatment of infantile-onset spinal muscular atrophy with nusinersen: a phase 2, open-label, dose-escalation study

2016 736 citations Richard S. Finkel, Claudia A. Chiriboga et al. The Lancet profile →
Pharmacokinetics, biodistribution and cell uptake of antisense oligonucleotides

2015 647 citations Richard S. Geary, Daniel A. Norris et al. Advanced Drug Delivery Reviews profile →
An antisense oligonucleotide against SOD1 delivered intrathecally for patients with SOD1 familial amyotrophic lateral sclerosis: a phase 1, randomised, first-in-man study

2013 492 citations Timothy M. Miller, Alan Pestronk et al. The Lancet Neurology profile →
Results from a phase 1 study of nusinersen (ISIS-SMN _Rx ) in children with spinal muscular atrophy

2016 460 citations Claudia A. Chiriboga, Kathryn J. Swoboda et al. Neurology profile →

Peers — A (Enhanced Table)

Peers by citation overlap · career bar shows stage (early→late) cites · hero ref

Name	h						Papers	Cites
Daniel A. Norris United States	20	2.4k	1.3k	509	456	358	38	3.7k
Wei Hua China	32	1.8k 0.8×	478 0.4×	215 0.4×	278 0.6×	163 0.5×	139	3.5k
Xingang Li China	38	1.9k 0.8×	652 0.5×	384 0.8×	416 0.9×	289 0.8×	170	4.3k
Gabriella Nicolini Italy	35	1.3k 0.5×	211 0.2×	260 0.5×	239 0.5×	241 0.7×	107	3.3k
Yoshiki Sekijima Japan	37	4.6k 1.9×	520 0.4×	415 0.8×	468 1.0×	251 0.7×	264	6.1k
Babette Weksler France	21	1.1k 0.5×	139 0.1×	81 0.2×	179 0.4×	322 0.9×	27	3.3k
Shujun Liu United States	35	2.6k 1.1×	312 0.2×	84 0.2×	127 0.3×	271 0.8×	88	4.2k
Anthony Régina Canada	24	1.4k 0.6×	227 0.2×	82 0.2×	52 0.1×	227 0.6×	39	3.1k
Antonia Aránega Spain	28	1.2k 0.5×	198 0.1×	263 0.5×	57 0.1×	56 0.2×	137	2.9k
Raheleh Farahzadi Iran	30	858 0.4×	555 0.4×	286 0.6×	149 0.3×	49 0.1×	78	2.2k

Countries citing papers authored by Daniel A. Norris

Since Specialization

Citations

This map shows the geographic impact of Daniel A. Norris's research. It shows the number of citations coming from papers published by authors working in each country. You can also color the map by specialization and compare the number of citations received by Daniel A. Norris with the expected number of citations based on a country's size and research output (numbers larger than one mean the country cites Daniel A. Norris more than expected).

Fields of papers citing papers by Daniel A. Norris

Since Specialization

Physical SciencesHealth SciencesLife SciencesSocial Sciences

This network shows the impact of papers produced by Daniel A. Norris. Nodes represent research fields, and links connect fields that are likely to share authors. Colored nodes show fields that tend to cite the papers produced by Daniel A. Norris. The network helps show where Daniel A. Norris may publish in the future.

Co-authorship network of co-authors of Daniel A. Norris

This figure shows the co-authorship network connecting the top 25 collaborators of Daniel A. Norris. A scholar is included among the top collaborators of Daniel A. Norris based on the total number of citations received by their joint publications. Widths of edges represent the number of papers authors have co-authored together. Node borders signify the number of papers an author published with Daniel A. Norris. Daniel A. Norris is excluded from the visualization to improve readability, since they are connected to all nodes in the network.

All Works

Sort: Min cites: Since: Top N: Style:

20 of 20 papers shown

Yamamoto, Yumi, et al.. (2023). Development of a population pharmacokinetic model to characterize the pharmacokinetics of intrathecally administered tominersen in cerebrospinal fluid and plasma. CPT Pharmacometrics & Systems Pharmacology. 12(9). 1213–1226. 4 indexed citations

Monine, Michael, Daniel A. Norris, Yanfeng Wang, & Ivan Nestorov. (2021). A physiologically-based pharmacokinetic model to describe antisense oligonucleotide distribution after intrathecal administration. Journal of Pharmacokinetics and Pharmacodynamics. 48(5). 639–654. 34 indexed citations

Jafar‐Nejad, Paymaan, Berit Powers, Armand Soriano, et al.. (2020). The atlas of RNase H antisense oligonucleotide distribution and activity in the CNS of rodents and non-human primates following central administration. Nucleic Acids Research. 49(2). 657–673. 62 indexed citations

Biliouris, Konstantinos, Wei Yin, Daniel A. Norris, et al.. (2018). A Semi‐Mechanistic Population Pharmacokinetic Model of Nusinersen: An Antisense Oligonucleotide for the Treatment of Spinal Muscular Atrophy. CPT Pharmacometrics & Systems Pharmacology. 7(9). 581–592. 22 indexed citations

Shemesh, Colby S., Rosie Z. Yu, Mark S. Warren, et al.. (2017). Assessment of the Drug Interaction Potential of Unconjugated and GalNAc3-Conjugated 2′-MOE-ASOs. Molecular Therapy — Nucleic Acids. 9. 34–47. 27 indexed citations

Finkel, Richard S., Claudia A. Chiriboga, Jiri Vajsar, et al.. (2016). Interim Results of a Phase 2 Clinical Study of Nusinersen (ISIS-SMNRx) in Patients with Infantile-Onset Spinal Muscular Atrophy (P5.004). Neurology. 86(16_supplement). 5 indexed citations

Finkel, Richard S., Claudia A. Chiriboga, Jiri Vajsar, et al.. (2016). Treatment of infantile-onset spinal muscular atrophy with nusinersen: a phase 2, open-label, dose-escalation study. The Lancet. 388(10063). 3017–3026. 736 indexed citations breakdown →

Geary, Richard S., Daniel A. Norris, Rosie Z. Yu, & C. Frank Bennett. (2015). Pharmacokinetics, biodistribution and cell uptake of antisense oligonucleotides. Advanced Drug Delivery Reviews. 87. 46–51. 647 indexed citations breakdown →

Yu, Rosie Z., John S. Grundy, Scott P. Henry, et al.. (2015). Predictive Dose-Based Estimation of Systemic Exposure Multiples in Mouse and Monkey Relative to Human for Antisense Oligonucleotides With 2′-O-(2-Methoxyethyl) Modifications. Molecular Therapy — Nucleic Acids. 4. e218–e218. 38 indexed citations

10.

Finkel, Richard S., John Day, Claudia A. Chiriboga, et al.. (2014). Results of a Phase 2 Open-Label Study of ISIS-SMNRx in Patients with Infantile (Type 1) Spinal Muscular Atrophy (S6.003). Neurology. 82(10_supplement). 8 indexed citations

11.

Rigo, Frank, Seung Chun, Daniel A. Norris, et al.. (2014). Pharmacology of a Central Nervous System Delivered 2′-O-Methoxyethyl–Modified Survival of Motor Neuron Splicing Oligonucleotide in Mice and Nonhuman Primates. Journal of Pharmacology and Experimental Therapeutics. 350(1). 46–55. 213 indexed citations

12.

Miller, Timothy M., Alan Pestronk, William David, et al.. (2013). An antisense oligonucleotide against SOD1 delivered intrathecally for patients with SOD1 familial amyotrophic lateral sclerosis: a phase 1, randomised, first-in-man study. The Lancet Neurology. 12(5). 435–442. 492 indexed citations breakdown →

13.

Chiriboga, Claudia A., Kathryn J. Swoboda, Basil T. Darras, et al.. (2013). Results of an Open-Label, Escalating Dose Study To Assess the Safety, Tolerability, and Dose Range Finding of a Single Intrathecal Dose of ISIS-SMN _Rx in Patients with Spinal Muscular Atrophy (S36.002). Neurology. 80(7_supplement). 7 indexed citations

14.

Jones, Nicholas, Melissa A. Pegues, Mark A. McCrory, et al.. (2012). A Selective Inhibitor of Human C-reactive Protein Translation Is Efficacious In Vitro and in C-reactive Protein Transgenic Mice and Humans. Molecular Therapy — Nucleic Acids. 1. e52–e52. 39 indexed citations

15.

Ruebsam, Frank, Zhongxiang Sun, Benjamin K. Ayida, et al.. (2008). Hexahydro-pyrrolo- and hexahydro-1H-pyrido[1,2-b]pyridazin-2-ones as potent inhibitors of HCV NS5B polymerase. Bioorganic & Medicinal Chemistry Letters. 18(18). 5002–5005. 10 indexed citations

16.

Cooper, Michael R., Elaine M. Rankin, D. Bissett, et al.. (2004). Initial phase I study of XR5944, a novel DNA and RNA targeting agent. Journal of Clinical Oncology. 22(14_suppl). 2100–2100. 2 indexed citations

17.

Norris, Daniel A., Glen Leesman, Patrick J. Sinko, & George M. Grass. (2000). Development of predictive pharmacokinetic simulation models for drug discovery. Journal of Controlled Release. 65(1-2). 55–62. 80 indexed citations

18.

Norris, Daniel A., et al.. (1999). Determining the absolute surface hydrophobicity of microparticulates using thin layer wicking. Journal of Controlled Release. 59(2). 173–185. 26 indexed citations

19.

Guo, Ailan, et al.. (1998). Characterization of the Regional Intestinal Kinetics of Drug Efflux in Rat and Human Intestine and in Caco-2 Cells. Pharmaceutical Research. 15(8). 1160–1167. 185 indexed citations

20.

Norris, Daniel A., et al.. (1985). The recent decline in TAT research.. Professional Psychology Research and Practice. 16(1). 26–28. 3 indexed citations

Rankless uses publication and citation data sourced from OpenAlex, an open and comprehensive bibliographic database. While OpenAlex provides broad and valuable coverage of the global research landscape, it—like all bibliographic datasets—has inherent limitations. These include incomplete records, variations in author disambiguation, differences in journal indexing, and delays in data updates. As a result, some metrics and network relationships displayed in Rankless may not fully capture the entirety of a scholar's output or impact.

Explore authors with similar magnitude of impact